Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…Abstract Number: 0669 • ACR Convergence 2021
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Background/Purpose: Data suggests that the number of patients with early-onset gout (EOG), defined as patients under the age of 40 years, is increasing1. There is…Abstract Number: 0671 • ACR Convergence 2021
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…Abstract Number: 1449 • ACR Convergence 2021
Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
Background/Purpose: Elevated serum urate is the most important risk factor for developing gout. However, in longitudinal cohort studies, a small proportion of people with normal…Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…Abstract Number: 1574 • ACR Convergence 2021
Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography
Background/Purpose: The diagnostic gold standard for gout remains aspiration and identification of monosodium urate (MSU) crystals under polarised light microscopy. Joint aspiration is invasive and…Abstract Number: 1578 • ACR Convergence 2021
NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
Background/Purpose: Both hyperuricemia and monosodium urate crystals induce persistent inflammation. In vitro, soluble urate can prime innate immune cells and promote NLRP3 inflammasome activation and…Abstract Number: 1581 • ACR Convergence 2021
Genetic Effects on the Transition from Hyperuricemia to Gout
Background/Purpose: There is clear evidence of genetic control of hyperuricemia resulting in increased gout risk, however genetic control of the transition from hyperuricemia to gout…Abstract Number: 0552 • ACR Convergence 2020
Fast Food Habits and Serum Urate Change in Young Adults: 15-Year Prospective Cohort Analysis
Background/Purpose: Fast food consumption has strong positive associations with weight gain and insulin resistance. Obesity and insulin resistance are, in turn, strongly associated with elevated…Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 0664 • ACR Convergence 2020
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…Abstract Number: 0667 • ACR Convergence 2020
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…Abstract Number: 0675 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
- 1
- 2
- 3
- …
- 5
- Next Page »